Long-Term Efficacy and Safety of Benralizumab Treatment for PDGFRA-Negative Hypereosinophilic Syndrome is a research paper published in The Journal of Allergy and Clinical Immunology In Practice (2025). On theSindex it has a DataRank of 0.366. It has been cited 8 times, with 6 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.330
From this paper's citation signal
Citation Network Contribution
0.0360
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 6 citers.
Arkansas Department of Agriculture
Grant: 2013\u20130697
National Institute of Allergy and Infectious Diseases
Grant: K23 AI171085
Intramural NIH HHS
Grant: ZIA AI001130
American Partnership for Eosinophilic Disorders
Clinical Center
Division of Intramural Research
AstraZeneca
FWCI
6.58
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals